Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CMP Pharma’s CaroSpir Now Available | Contract Pharma

What are you searching for?

Sign in
Breaking News

CMP Pharma’s CaroSpir Now Available

First and only oral liquid dosage form of potassium-sparing diuretic spironolactone approved by FDA

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CMP Pharma’s CaroSpir, the first FDA-approved oral liquid dosage form of the potassium-sparing diuretic spironolactone, is now available. CaroSpir was approved on August 4.
 
CaroSpir oral suspension is for adult patients who have difficulty swallowing, or who cannot swallow tablets. It provides a stable and consistent dose of spironolactone. Previously, patients that required a liquid form of spironolactone have had to rely on unapproved pharmacy compounded formulations, which typically have limited shelf life, are not quality control tested for potency and sterility/bioburden. 
 
“CaroSpir is intended for a subset of the patient population that needs spironolactone, but has difficulty swallowing or inability to swallow. Until today there was no FDA-approved oral suspension of spironolactone to satisfy this unmet need. The availability of CaroSpir now gives healthcare providers and appropriate patients a convenient, safe and approved liquid option,” said Gerald Sakowski, chief executive officer of CMP Pharma, Inc.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics